论文部分内容阅读
目的观察辛伐他汀治疗阵发性心房颤动的效果。方法 87例阵发性心房颤动患者,随机分为治疗组(辛伐他汀加胺碘酮,45例)及对照组(单用胺碘酮,42例),观察6个月.比较两组的C反应蛋白(CRP)水平、复发率及不良反应。结果治疗组的CRP水平较对照组明显降低[(27.89±7.86)ng/ml;(32.57±8.75)ng/m1,P<0.05]。治疗组复发率26.6%(12/45),显著低于对照组的47.6%(20/42),P<0.05。结论辛伐他汀可能通过抑制炎症反应,减少阵发性房颤的复发。
Objective To observe the effect of simvastatin on paroxysmal atrial fibrillation. Methods Eighty-seven patients with paroxysmal atrial fibrillation were randomly divided into treatment group (simvastatin plus amiodarone, 45 cases) and control group (amiodarone alone, 42 cases) for 6 months.Compared the two groups C-reactive protein (CRP) levels, relapse rates and adverse reactions. Results The CRP level in the treatment group was significantly lower than that in the control group [(27.89 ± 7.86) ng / ml; (32.57 ± 8.75) ng / m1, P <0.05]. The recurrence rate was 26.6% (12/45) in the treatment group, which was significantly lower than that in the control group (47.6%, 20/42) (P <0.05). Conclusion Simvastatin may reduce the recurrence of paroxysmal atrial fibrillation by inhibiting the inflammatory reaction.